Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

2019 Editor's Choice Collections.

Cunningham C, Dixon LB, Sawhney R, Robitz R, Richards M, Rodríguez Penney AT, Jordan A, Colon-Rivera H, Goldman ML, Zingman MA, Rolin SA.

Psychiatr Serv. 2020 Jan 1;71(1):105-107. doi: 10.1176/appi.ps.71103. No abstract available.

PMID:
31892287
2.

Estimating Premorbid Ability in Rehabilitation Patients Using the Test of Premorbid Functioning and Wide Range Achievement Test-Fourth Edition.

Rolin SN, Davis JJ, Miller JB.

Assessment. 2019 Nov 13:1073191119887441. doi: 10.1177/1073191119887441. [Epub ahead of print]

PMID:
31718236
3.

Examining the Cognitive Proficiency Index in rehabilitation patients.

Rolin SN, Mullen CM, Vaccariello E, Davis JJ.

Appl Neuropsychol Adult. 2019 Sep 18:1-10. doi: 10.1080/23279095.2019.1666269. [Epub ahead of print]

PMID:
31530025
4.

Perspectives of Individuals With Serious Mental Illness on a Reverse-Colocated Care Model: A Qualitative Study.

Talley RM, Rolin SA, Trejo BN, Goldman ML, Alves-Bradford JE, Dixon LB.

Psychiatr Serv. 2019 Sep 1;70(9):793-800. doi: 10.1176/appi.ps.201800480. Epub 2019 May 21.

PMID:
31109264
5.

Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness.

Brucato G, Appelbaum PS, Masucci MD, Rolin S, Wall MM, Levin M, Altschuler R, First MB, Lieberman JA, Girgis RR.

Neuropsychopharmacology. 2019 Apr;44(5):907-914. doi: 10.1038/s41386-018-0304-5. Epub 2018 Dec 27.

6.

Recent violence and legal involvement among young adults with early psychosis enrolled in Coordinated Specialty Care.

Rolin SA, Marino LA, Pope LG, Compton MT, Lee RJ, Rosenfeld B, Rotter M, Nossel I, Dixon L.

Early Interv Psychiatry. 2019 Aug;13(4):832-840. doi: 10.1111/eip.12675. Epub 2018 May 9.

7.

Why We Need to Enhance Suicide Postvention: Evaluating a Survey of Psychiatrists' Behaviors after the Suicide of a Patient.

Erlich MD, Rolin SA, Dixon LB, Adler DA, Oslin DW, Levine B, Berlant JL, Goldman B, Koh S, First MB, Pabbati C, Siris SG.

J Nerv Ment Dis. 2017 Jul;205(7):507-511. doi: 10.1097/NMD.0000000000000682.

8.

Characteristics and Service Use of Older Adults with Schizoaffective Disorder Versus Older Adults with Schizophrenia and Bipolar Disorder.

Rolin SA, Aschbrenner KA, Whiteman KL, Scherer E, Bartels SJ.

Am J Geriatr Psychiatry. 2017 Sep;25(9):941-950. doi: 10.1016/j.jagp.2017.03.014. Epub 2017 Apr 3.

9.

Evidence-based science policy for mental health in a post-truth era.

Pincus HA, Rolin SA.

Lancet Psychiatry. 2017 Apr;4(4):270-272. doi: 10.1016/S2215-0366(17)30050-0. Epub 2017 Feb 7. No abstract available.

10.

Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.

DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr.

Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4. Review.

11.

A mixed methods exploration of family involvement in medical care for older adults with serious mental illness.

Aschbrenner KA, Pepin R, Mueser KT, Naslund JA, Rolin SA, Faber MJ, Bartels SJ.

Int J Psychiatry Med. 2014;48(2):121-33. doi: 10.2190/PM.48.2.e.

12.

Activating older adults with serious mental illness for collaborative primary care visits.

Bartels SJ, Aschbrenner KA, Rolin SA, Hendrick DC, Naslund JA, Faber MJ.

Psychiatr Rehabil J. 2013 Dec;36(4):278-88. doi: 10.1037/prj0000024. Epub 2013 Nov 11.

13.

A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: a practical guide.

Laloy J, Mullier F, Alpan L, Mejia J, Lucas S, Chatelain B, Toussaint O, Masereel B, Rolin S, Dogné JM.

Nanotoxicology. 2014 Mar;8(2):220-32. doi: 10.3109/17435390.2013.788750. Epub 2013 Apr 15.

PMID:
23521718
14.

Finger Tapping: Why Can't We Alternate Hands?

Eng K, Rolin S, Fazio R, Biddle C, O'Grady M, Denney R.

Appl Neuropsychol Adult. 2013 Jul-Sep;20(3):187-191. doi: 10.1080/09084282.2012.684114. Epub 2013 Feb 5.

PMID:
23384032
15.

Effects of SiC nanoparticles orally administered in a rat model: biodistribution, toxicity and elemental composition changes in feces and organs.

Lozano O, Laloy J, Alpan L, Mejia J, Rolin S, Toussaint O, Dogné JM, Lucas S, Masereel B.

Toxicol Appl Pharmacol. 2012 Oct 15;264(2):232-45. doi: 10.1016/j.taap.2012.08.004. Epub 2012 Aug 15.

PMID:
22981607
16.

Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials.

Laloy J, Robert S, Marbehant C, Mullier F, Mejia J, Piret JP, Lucas S, Chatelain B, Dogné JM, Toussaint O, Masereel B, Rolin S.

Nanotoxicology. 2012 Mar;6(2):213-32. doi: 10.3109/17435390.2011.569096. Epub 2011 Apr 13.

PMID:
21486188
17.

BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.

Cherdon C, Rolin S, Hanson J, Ooms A, de Leval L, Drion P, Michiels C, Pirotte B, Masereel B, Sakalihassan N, Defraigne JO, Dogné JM.

Prostaglandins Other Lipid Mediat. 2011 Apr;94(3-4):124-32. doi: 10.1016/j.prostaglandins.2011.03.001. Epub 2011 Mar 21.

PMID:
21397034
18.

Acupuncture for tension-type headache: a meta-analysis of randomized, controlled trials.

Davis MA, Kononowech RW, Rolin SA, Spierings EL.

J Pain. 2008 Aug;9(8):667-77. doi: 10.1016/j.jpain.2008.03.011. Epub 2008 May 22.

PMID:
18499526
19.

Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation.

Thiry A, Rolin S, Vullo D, Frankart A, Scozzafava A, Dogné JM, Wouters J, Supuran CT, Masereel B.

Eur J Med Chem. 2008 Dec;43(12):2853-60. doi: 10.1016/j.ejmech.2008.02.018. Epub 2008 Feb 29.

PMID:
18406497
20.

Synthesis and pharmacological evaluation of a new targeted drug carrier system: beta-cyclodextrin coupled to oxytocin.

Bertolla C, Rolin S, Evrard B, Pochet L, Masereel B.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1855-8. doi: 10.1016/j.bmcl.2008.02.017. Epub 2008 Feb 10.

PMID:
18296049
21.

BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.

Rolin S, Hanson J, Vastersaegher C, Cherdon C, Pratico D, Masereel B, Dogne JM.

Prostaglandins Other Lipid Mediat. 2007 Aug;84(1-2):14-23. Epub 2007 Mar 13.

PMID:
17643884
22.

Cardiovascular haemodynamics and ventriculo-arterial coupling in an acute pig model of coronary ischaemia-reperfusion.

Lanoye L, Segers P, Tchana-Sato V, Rolin S, Dogne JM, Ghuysen A, Lambermont B, Hanson J, Desaive T, Verdonck P, D'Orio V, Kolh P.

Exp Physiol. 2007 Jan;92(1):127-37. Epub 2006 Oct 12.

23.

Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.

Kolh P, Rolin S, Tchana-Sato V, Pétein M, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Masereel B, D'Orio V, Dogne JM.

Prostaglandins Other Lipid Mediat. 2006 Mar;79(1-2):53-73. Epub 2005 Dec 22.

24.

Prostanoids as pharmacological targets in COPD and asthma.

Rolin S, Masereel B, Dogné JM.

Eur J Pharmacol. 2006 Mar 8;533(1-3):89-100. Epub 2006 Feb 3. Review.

PMID:
16458293
25.

Synthesis, molecular modelling and enzymatic evaluation of (+/-)3,5-diphenyl-2-thioxoimidazolidin-4-ones as new potential cyclooxygenase inhibitors.

Gauthier MP, Michaux C, Rolin S, Vastersaegher C, de Leval X, Julémont F, Pochet L, Masereel B.

Bioorg Med Chem. 2006 Feb 15;14(4):918-27. Epub 2005 Oct 7.

PMID:
16214349
26.

Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig.

Dogné JM, Rolin S, Pétein M, Tchana-Sato V, Ghuysen A, Lambermont B, Hanson J, Magis D, Segers P, Pirotte B, Masereel B, Drion P, D'Orio V, Kolh P.

Thromb Res. 2005;116(5):431-42. Epub 2005 Mar 23.

27.

Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.

Ghuysen A, Dogné JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V.

Cardiovasc Drug Rev. 2005 Spring;23(1):1-14. Review.

PMID:
15867944
28.

In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.

Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogné JM.

J Pharmacol Exp Ther. 2005 Apr;313(1):293-301. Epub 2004 Dec 30.

PMID:
15626721
29.

Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.

Rolin S, Dogne JM, Vastersaegher C, Hanson J, Masereel B.

Prostaglandins Other Lipid Mediat. 2004 Oct;74(1-4):75-86.

PMID:
15560117
30.

Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties.

Chazalette C, Masereel B, Rolin S, Thiry A, Scozzafava A, Innocenti A, Supuran CT.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6.

PMID:
15501040
31.

Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity.

Ilies MA, Masereel B, Rolin S, Scozzafava A, Câmpeanu G, Cîmpeanu V, Supuran CT.

Bioorg Med Chem. 2004 May 15;12(10):2717-26.

PMID:
15110853
32.

Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.

Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, Masereel B, Pirotte B.

J Pharmacol Exp Ther. 2004 May;309(2):498-505. Epub 2004 Jan 23.

PMID:
14742735
33.

A pharmacophore model for sulphonyl-urea (-cyanoguanidine) compounds with dual action, thromboxane receptor antagonists and thromboxane synthase inhibitors.

Michaux C, Dogné JM, Rolin S, Masereel B, Wouters J, Durant F.

Eur J Med Chem. 2003 Jul-Aug;38(7-8):703-10.

PMID:
12932901
34.

BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.

Rolin S, Petein M, Tchana-Sato V, Dogne JM, Benoit P, Lambermont B, Ghuysen A, Kolh P, Masereel B.

J Pharmacol Exp Ther. 2003 Jul;306(1):59-65. Epub 2003 Apr 29.

PMID:
12721335
35.

Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function.

Dogné JM, de Leval X, Kolh P, Sanna V, Rolin S, Michaux C, Mauer M, David JL, Masereel B, Pirotte B.

Prostaglandins Leukot Essent Fatty Acids. 2003 Jan;68(1):49-54.

36.

Therapeutic potential of thromboxane inhibitors in asthma.

Dogné JM, de Leval X, Benoit P, Rolin S, Pirotte B, Masereel B.

Expert Opin Investig Drugs. 2002 Feb;11(2):275-81. Review.

PMID:
11829716
37.

Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties.

Masereel B, Rolin S, Abbate F, Scozzafava A, Supuran CT.

J Med Chem. 2002 Jan 17;45(2):312-20.

PMID:
11784136
38.

Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.

Rolin S, Dogné JM, Michaux C, Delarge J, Masereel B.

Prostaglandins Leukot Essent Fatty Acids. 2001 Aug;65(2):67-72.

PMID:
11545621
39.

Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.

Dogné JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, Kolh P, Damas J, David JL, Masereel B.

Cardiovasc Drug Rev. 2001 Summer;19(2):87-96. Review.

PMID:
11484064
40.

Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.

Dogné JM, Wouters J, Rolin S, Michaux C, Pochet L, Durant F, Delarge J, Masereel B.

J Pharm Pharmacol. 2001 May;53(5):669-80.

PMID:
11370706
41.

Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.

Michaux C, Rolin S, Dogné JM, Durant F, Masereel B, Delarge J, Wouters J.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1019-22.

PMID:
11327579
42.

Dexamethasone increases intracellular cyclic AMP concentration in murine T lymphocyte cell lines.

Baus E, Van Laethem F, Andris F, Rolin S, Urbain J, Leo O.

Steroids. 2001 Jan;66(1):39-47.

PMID:
11090657
43.

Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.

Dogné JM, de Leval X, Neven P, Rolin S, Wauters J, David JL, Delarge J, Massereel B.

Prostaglandins Leukot Essent Fatty Acids. 2000 May;62(5):311-7.

PMID:
10883063
44.

Slender and stumpy bloodstream forms of Trypanosoma brucei display a differential response to extracellular acidic and proteolytic stress.

Nolan DP, Rolin S, Rodriguez JR, Van Den Abbeele J, Pays E.

Eur J Biochem. 2000 Jan;267(1):18-27.

45.

BM 144: an original thromboxane A2 receptor antagonist derived from torasemide.

Dogné JM, Neven P, Damas J, Fontaine J, Rolin S, De Leval X, Delarge J, Masereel B.

J Pharm Belg. 1999 Mar-Apr;54(2):57-8.

PMID:
10380411
46.

Mild acid stress as a differentiation trigger in Trypanosoma brucei.

Rolin S, Hancocq-Quertier J, Paturiaux-Hanocq F, Nolan DP, Pays E.

Mol Biochem Parasitol. 1998 Jun 1;93(2):251-62.

PMID:
9662709
47.

The GPI-phospholipase C of Trypanosoma brucei is nonessential but influences parasitemia in mice.

Webb H, Carnall N, Vanhamme L, Rolin S, Van Den Abbeele J, Welburn S, Pays E, Carrington M.

J Cell Biol. 1997 Oct 6;139(1):103-14.

48.

Expression of a variant surface glycoprotein of Trypanosoma gambiense in procyclic forms of Trypanosoma brucei shows that the cell type dictates the nature of the glycosylphosphatidylinositol membrane anchor attached to the glycoprotein.

Paturiaux-Hanocq F, Zitzmann N, Hanocq-Quertier J, Vanhamme L, Rolin S, Geuskens M, Ferguson MA, Pays E.

Biochem J. 1997 Jun 15;324 ( Pt 3):885-95. Erratum in: Biochem J 1998 Mar 15;330(Pt 3):1481.

49.

Simultaneous but independent activation of adenylate cyclase and glycosylphosphatidylinositol-phospholipase C under stress conditions in Trypanosoma brucei.

Rolin S, Hanocq-Quertier J, Paturiaux-Hanocq F, Nolan D, Salmon D, Webb H, Carrington M, Voorheis P, Pays E.

J Biol Chem. 1996 May 3;271(18):10844-52.

50.

Trypanosoma brucei: stimulation of adenylate cyclase by proventriculus and esophagus tissue of the tsetse fly, Glossina morsitans morsitans.

van den Abbeele J, Rolin S, Claes Y, Le Ray D, Pays E, Coosemans M.

Exp Parasitol. 1995 Dec;81(4):618-20. No abstract available.

PMID:
8543006

Supplemental Content

Support Center